Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. - Wikidata - awgldk - TriplyDB

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

http://www.wikidata.org/entity/Q33372867

about

Mechanism of action of lenalidomide in hematological malignancies Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma Thrombopoietin mimetics for patients with myelodysplastic syndromes Identification of RPS14 as a 5q- syndrome gene by RNA interference screen Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome Cytogenetic features in myelodysplastic syndromes Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML Thalidomide analogues as anticancer drugs Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management Defects in spliceosomal machinery: a new pathway of leukaemogenesis Progress towards mechanism-based treatment for Diamond-Blackfan anemia Infections in myelodysplastic syndromes Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes Myelodysplastic syndromes: what do hospitalists need to know?Iron chelation therapy in myelodysplastic syndromes: where do we stand?New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice PP2A: The Achilles Heal in MDS with 5q Deletion Therapy-related myeloid neoplasms: pathobiology and clinical characteristics Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Established and emerging targeted therapies in the myelodysplastic syndromes.Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).Solving the mystery of myelodysplasia.Myelodysplastic syndromes: the role of the immune system in pathogenesis.Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.The role of lenalidomide in the management of myelodysplasia with del 5q.Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.Pomalidomide is active in the treatment of anemia associated with myelofibrosis Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.Thrombocytopenia in patients with myelodysplastic syndromes.A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.A phase-2 trial of low-dose pomalidomide in myelofibrosis.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.

P2860

Q21198872-3FD79D9D-D5FF-4C25-A365-78AF0D459532 Q21285161-76B3EA59-C1BB-4687-95D3-38ACE0D40317 Q24198060-E4354795-9599-4244-B9FC-9FF064979BAA Q24306795-40A9856F-B789-413E-8037-5F6E38238B66 Q24632949-348F2D15-4D77-4EC9-9784-7F942BD364EF Q24644654-7FBA2B6E-71D7-47FC-9B22-A47F1DC3E952 Q24645177-CA42B4D8-E19C-4C6B-85A7-D49705172AD1 Q24670383-590BF00C-4783-4450-B5EF-80EDE0DD5E96 Q26778754-FA73BB83-A2CF-4E49-8760-DB2C45FAEDE0 Q26796240-D6C9148B-DED2-42C8-9ECB-BB82AAC41637 Q26823040-B0F927D8-DB3B-4EF0-9CC2-56F9E3B61FB1 Q26823710-77019C98-9386-4E3E-A785-8728DA619117 Q26859275-0466FC03-2514-45E1-AD22-6D28232C6C14 Q26863182-1FB2C6E8-2C7B-4E2E-BAEF-40F78E27E0C6 Q27011372-7F5F9F8C-EDF6-40A4-8B43-518A865A4E1B Q27011747-53C38457-7719-47E4-9F1F-A3283BBAF0BA Q27016511-5F0D2447-39B4-4319-A3E0-ABA3FE44C436 Q27690852-4DC00CA8-FF15-4778-B24F-8BAA309738BA Q28386366-D00599D0-8AA3-4437-B393-F0C2A7813028 Q28387115-636C0B94-B000-4039-8305-8D3F4BDD2856 Q28472171-593FF83D-BB45-4235-874F-63E47993C945 Q28534997-470CA06D-255A-4735-8C4A-A2A22962F885 Q30235355-C8A4CB6F-B9F7-47B6-A3B6-D3CCB15A3D29 Q30245476-AF817AD6-0A01-4464-AB6F-063993A66106 Q30358639-B5415414-702D-4D2F-A3FB-EB79A2A64082 Q30987570-1CB21C8D-B92E-4735-9814-CF24131F1C3E Q33319613-71AAADA3-6D15-4B74-BD6A-DFCBD377BBBF Q33351527-3AFB45E8-2E72-4F0E-98D9-76271D414B5D Q33373984-B67B908E-F680-4DAF-8BCA-CF7F5EB95AF3 Q33378398-E7E32AF8-6A3B-4F3A-94DE-AF6003DF4731 Q33379562-2418D91D-4D35-49B6-82C1-9826274341E3 Q33382047-399F3127-CFE5-47C7-95A5-1059892794CF Q33385644-C7DCC71B-99BD-4720-BA1A-AEFD3263B97F Q33386057-9FDA2329-5EDA-4513-B0D1-38D8C6861142 Q33387037-0E7B17E7-4F18-467A-9F8D-A2B01FA0ECE8 Q33390639-9A6F77D3-B3F7-411F-8875-DE0ED9A10CF4 Q33392683-5D0396CE-86DA-4FCC-9743-F72B02D78CEE Q33392689-44182D11-BEAB-4C49-BE6E-6C0E47E0719D Q33393647-509B01CB-1E2F-42E8-B518-87F3B1DB5A13 Q33398044-F12487E8-90CB-4643-B3EF-B64E55DB0605

P2860

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

http://www.wikidata.org/entity/Q33372867

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

@ast

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

@en

type

label

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

@ast

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

@en

prefLabel

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

@ast

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

@en

P1433

Q33372867-BC792EBA-ED1A-4C7A-9109-8E8E8E192558

P1476

Q33372867-146D9B58-416E-4806-8B3C-F1959F8CA114

P2093

Q33372867-061F5A63-5F70-4D9F-9517-51722083BCD1

Q33372867-0BD77082-B4E7-4BC5-9E5B-A864495C7772

Q33372867-2189B4D3-8CB4-4EA4-8A83-8217714C1408

Q33372867-345E4AC9-3F4E-438E-B9FC-7DF525D56681

Q33372867-422DACA7-CFF6-4A53-92E8-3DCE811F76E2

Q33372867-4998CE2A-94E9-4665-AF97-4DD4C84B4D5A

Q33372867-57E52F7A-8C2E-40D2-9CE6-3CDE17CB2014

Q33372867-5FC14E8A-099E-4815-95DD-86B6B393B5BB

Q33372867-6CBD874D-E8E9-4141-8458-FAD174EF6C09

Q33372867-6F6B2437-10B4-4394-91FD-9091B10AA378

P304

Q33372867-4920825A-412B-4448-B70E-54889C228ABE

P31

Q33372867-78708708-088E-46A0-8159-BB47FFCEB89E

P356

Q33372867-E5102E37-5FE5-4161-AD67-EBAF2CAFE6B8

P407

Q33372867-5EDDF0F1-C7A2-455F-AB93-CCCEA93AC36F

P433

Q33372867-4B24EF26-32F1-42C6-8E3A-27D92DF683B0

P478

Q33372867-D0D446BE-6E27-4164-B721-E1085088B1BC

P577

Q33372867-E8C5FBD2-743F-4B45-A5EA-491BB7975697

P698

Q33372867-4524C343-66EA-4FBF-9E42-2A0B04B22FDA

P356

P1433

The New England Journal of Medicine

P1476

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

@en

P2093

Alan List

http://www.w3.org/2001/XMLSchema#string

Aristotle Giagounidis

http://www.w3.org/2001/XMLSchema#string

Azra Raza

http://www.w3.org/2001/XMLSchema#string

Bayard Powell

http://www.w3.org/2001/XMLSchema#string

Craig Reeder

http://www.w3.org/2001/XMLSchema#string

Deborah Thomas

http://www.w3.org/2001/XMLSchema#string

Eric Feldman

http://www.w3.org/2001/XMLSchema#string

Gordon Dewald

http://www.w3.org/2001/XMLSchema#string

Jerome Zeldis

http://www.w3.org/2001/XMLSchema#string

John Bennett

http://www.w3.org/2001/XMLSchema#string

P304

1456-1465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA061292

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

355

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17021321

http://www.w3.org/2001/XMLSchema#string